



OS DOENTES COM FA PERSISTENTE DE LONGA DURAÇÃO DEVEM SER CANDIDATOS A ABLAÇÃO POR CATETER? **NÃO!**



Mário Oliveira
Laboratório de Electrofisiologia
Serviço de Cardiologia - Hospital de Santa Marta



Congresso
**Novas Fronteiras
em Cardiologia**
7 a 9 de Fevereiro de 2014



FUNDADA 1901 mundodeportivo.com

MD TE OFRECE UNOS

ALTAVOCES PORTÁTILES

COMPATIBLE CON TODOS LOS SMARTPHONES, MP3 Y MP4



HOY LA CARTILLA

POR SÓLO **14,95** EUROS

EURO - DOMINGO 10 DE NOVIEMBRE DE 2013




→ **MOTOS MD EN EL GP DE LA COMUNITAT VALENCIANA 11 H. TELE 5**

Duelo en Ericeira

El título de MotoGP se decide hoy entre Márquez y Lorenzo en una cita apasionante

La corona de Moto 3 es cosa de tres: Salom, Viñales y Rins llegan separados por ¡5 puntos!

WRC: CAMPEÃO ENTRE A SHARAH E MORTO CARLOS



OGIER
SOZINHO EM CASA




DUROS DE ROER

A REVISTA DE CINEMA MAIS VENDEDIDA NO MUNDO

EMPIRE



ENTREVISTA EXCLUSIVA
SARAH MILTON
Tommy Lee Jones

TOM CRUISE EM EXCLUSIVO
MISSÃO IMPOSSÍVEL:

FA PERSISTENTE DE LONGA DURAÇÃO
TRATADA COM ABLAÇÃO



OLIVEIRA IMPEDIDO DE FALAR

Several randomized clinical trials have shown superiority of catheter ablation over AAD therapy to achieve SR and to improve symptoms and quality of life


Parkash, et al. JCE 2011

Indications for catheter atrial fibrillation ablation

- Symptomatic AF refractory or intolerant to at least one class 1 or 3 antiarrhythmics.
- In rare clinical situations, it may be appropriate to perform ablation as 1st-line therapy.



Expert Consensus, HRS/EHRA/ECAS 2012



Episodes of ≤48h terminated with cardioversion are classified as paroxysmal AF

INDICATIONS FOR CATHETER ABLATION of AF

Symptomatic AF refractory or intolerant to at least one Class 1 or 3 antiarrhythmic medication

Paroxysmal: Catheter ablation is recommended*

I A

Persistent: Catheter ablation is reasonable

IIa B

Longstanding Persistent: Catheter ablation may be considered

IIb B

Symptomatic AF prior to initiation of antiarrhythmic drug therapy with a Class 1 or 3 antiarrhythmic agent

Paroxysmal: Catheter ablation is reasonable

IIa B


Persistent: Catheter ablation may be considered

IIb C

Longstanding Persistent: Catheter ablation may be considered

IIb C

In persistent and long-standing persistent AF results are not yet satisfactory

Luigi Di Biase, Current Opin Cardiol 2013



M. Alessie


ATRIAL REMODELING


... once initiated, AF alters atrial electrical and structural properties in a way that promotes its own maintenance and recurrences.

... with resistance to sinus rhythm conversion.

Chou & Chen, JCE 2008

Muntean et al., J Clin Exp Cardiol 2013






Patients with long-lasting persistent vs. persistent AF have:

- larger LA surface area ($134 \pm 38 \text{ cm}^2$ vs. $98 \pm 9 \text{ cm}^2$, $p=0.02$)
- higher amount of atrial fibrosis (DE-MRI) ($70 \pm 16 \text{ cm}^2$ vs. $49 \pm 10 \text{ cm}^2$, $p=0.01$)
- more CFAE extent ($54 \pm 16 \text{ cm}^2$ vs. $28 \pm 15 \text{ cm}^2$, $p=0.02$)
- shorter baseline AF CL ($147 \pm 10 \text{ ms}$ vs. $182 \pm 14 \text{ ms}$, $p=0.01$)

Impact of type of AF and repeat catheter ablation on long-term freedom from AF: Results from a multicenter study



Bhargava, et al. Heart Rhythm 2009

RECURRENCE OF AT/AF FOLLOWING RF CATHETER ABLATION OF AF

Predictors of Late Recurrence in Those with Early Recurrence

Clinical

- Older age¹⁷
- Genetic factors (presence of 4q25 variants)⁵

AF History

- Persistent/permanent AF^{7,18,17}
- Higher number of previously ineffective antiarrhythmic drugs²³
- Symptomatic ERAT (especially if > 6 hours duration)²⁰
- Timing of ERAT (after the second month)²⁷

Echocardiographic Parameters

- Left atrial enlargement^{9,14,28}

Electrical Characteristics

- Increased P-wave dispersion⁹
- Lack of electrical remodeling (P max and P-wave dispersion)²⁶

Procedural Variables

- Incomplete pulmonary vein isolation¹⁵
- No termination of AF or cardioversion required during index ablation procedure^{14,15}
- Higher number of ablation lesions²³
- Prolonged ablation and procedure time²³
- Inducibility of AF or atrial tachyarrhythmia during index ablation procedure²³
- Cavotricuspid isthmus ablation²³
- Electrogram-based ablation²⁸

Increase delayed enhancement
MRI (fibrosis)

AF ABLATION

1st ⇒ SELECT THE RIGHT PATIENT !

Type of AF

LA diameter

Fibrosis


Co-morbidities

Age


LVEF

2nd ⇒ DEFINE THE “BEST” STRATEGY !

Atrial Fibriosis Helps Select the Appropriate Patient and Strategy in Catheter Ablation of Atrial Fibrillation: A DE-MRI Guided Approach




Nakoum et al, JCE 2012



Impact of left atrial fibrosis and left atrial size on the outcome of catheter ablation for atrial fibrillation

Uijl DW, et al. Heart 2011

n=174




LA volume and AF type predict AF recurrence after catheter ablation


n=407

Adragão, et al (in press)

ADJUSTED RECURRENCE RISK OF ATRIAL FIBRILLATION FOR GROUPS



Long-term Outcomes of Catheter Ablation of Atrial Fibrillation: A Systematic Review and Meta-analysis




Outcomes of long-standing persistent AF ablation: a systematic review

Brooks, et al; Heart Rhythm 2010

Author	N	Technique	Success			Complication rate (%)
			Single	Multiple	AAD	
Kanagaratnam				—	0.62	5.6
Lim				0.37 (1.7)	0.45	3.9
Yamada				0.43 (1.5)	—	—
Pappone				—	0.68	TG
Cheema				0.54 (1.2)	—	9.8
Elayi ^{RCT2}				0.56 (1.3)	0.85	0.0
Oral ^{RCT3}				0.68 (1.4)	—	TG
Oral ^{RCT1}				—	—	0.0
Vasamreddy				—	0.70	TG
Oral				—	—	0.0
Elayi ^{RCT2}				0.17 (1.3)	0.28	0.0
Earley				0.74 (1.6)	—	11.9
Seow				0.54 (1.5)	0.86	7.1
Miyazaki				—	0.60*	0.0
Fiala				0.66 (1.5)	0.87	—
Sanders	27	BOX	0.44	0.63 (1.4)	—	7.4
Chen	10	BOX	0.50	0.60 (1.5)	—	—
Kumagai	24	BOX	0.42	0.46 (1.1)	0.88	TG
Nademanee	64	CFAE	0.63	0.77 (1.2)	—	TG
Oral ^{RCT1}	40	CFAE	0.33	—	—	0.0
Oral	100	CFAE	0.33	0.57 (1.5)	—	3.0
Oral ^{RCT4}	33	CFAE†	0.24	0.52 (1.4)	—	3.0
Oral ^{RCT4}	33	CFAE‡	0.30	0.58 (1.2)	—	0.0
Schmitt	30	PVI + CFAE	0.50	—	—	TG
Estner	35	PVI + CFAE	0.51	0.74	—	0.0
Li	92	PVAI + CFAE	0.58	—	—	5.4
Porter	25	PVAI + LIN + CFAE	0.68	—	—	4.0
Elayi ^{RCT2}	49	PVAI + CFAE	0.61	0.80 (1.2)	0.94	6.1
Oral ^{RCT3}	50	PVAI + CFAE	0.36	0.60 (1.4)	—	0.0
Haissaguerre	60	STEPWISE	0.62	0.88 (1.5)	—	5.0
Sacher	43	STEPWISE	—	0.70 (1.4)	0.84	—
Takahashi	40	STEPWISE	0.55	0.83 (1.4)	0.90	2.5
Rostock	88	STEPWISE	0.38	0.81 (1.8)	—	3.2
O'Neill	153	STEPWISE	0.48	0.74 (1.5)	0.89	3.9

**A 1 Per 1,000
Mortality Rate After Catheter
Ablation of Atrial Fibrillation
An Acceptable Risk?***

- substrate (and procedure) more complex
- often accompanied by significant comorbidities
- fewer patients with complete success
- > pts need a second (and third...) ablation



Arritmias tratadas sem intervenção das mãos

A ablação, seja computadorizada ou tradicional, é elegível para cerca de 50% dos doentes, excepto aqueles que "têm as aurículas dilatadas, que não têm um bom estado geral de saúde ou que já estão em fibrilhação auricular há vários anos"

Pedro Adragão, In Diário de Notícias,
23/Abril/2009



Clinical outcome of ablation for long-standing persistent atrial fibrillation with or without defragmentation

Complete defragmentation (CFAE, sites with a significant electrogram offset suggesting a local re-entrant wavefront, regions with a shorter CL) using Stereotaxis Magnetic Navigation is associated with a higher number of minor complications and longer procedure times, and thus compromises efficiency without improving efficacy.



...o que se faz a mais além do isolamento das veias pulmonares é muito duvidoso!

“... se não fizermos nada no início já não vamos conseguir obter resultados. Já vai tarde demais...” Pedro Adragão, 3º Curso de Revisão e Atualização em Medicina Cardiovascular, 1/Fev./2014

Na FA persistente, para além do **isolamento das VP**, podem ser aplicadas lesões adicionais para eliminar **focos trigger extra-VP** ou para criar **linhas no teto e parede posterior da AE, SIA, istmo mitral ou zona de transição VP-AAE**. A identificação e abolição de potenciais fracionados auriculares complexos (**CFAE**) têm permitido melhorar resultados segundo alguns autores. Também o reconhecimento do papel do SNA nos mecanismos da FA tem levado ao desenvolvimento de técnicas para localização dos **gânglios autonómicos cardíacos** por estimulação neurofisiológica e sua ablação específica.

Oliveira M. Rev Port Cardiol 2009

Catheter Ablation for the treatment of AF

Maze reproduction

Schwarz 1994

Right atrial linear lesions

Haïssaguerre 1994

Right and left atrial linear lesions

Haïssaguerre 1996

PV foci ablation

Jaïs / Haïssaguerre 1998

Ostial PV isolation

Haïssaguerre 2000

Circumferential PV ablation (CPVA)


Pappone 2000

Lin 2003

Maroucche / Natale 2004




Ouyang / Kuck 2004

Long-standing persistent AF ablation outcomes Short- and long-term success




Ablation site	Power (Watts)	Usual total duration of radiofrequency delivery (mins)
Coronary Sinus	15 -25	4-8
Posterior wall LA	25 -30	3-6
Anterior wall LA	30 -35	3-6
Inferior LA	30 -40	5-10
Roof LA	25 -30	10-15
PVs	30	25-40
Septum LA	30	3-6
Right atrium	20 -35	0-20
Mitral Isthmus	30 -35	10-20

CC Chou, 2011



too much tools may be useless!...







BLANCHARD GIRÃO

Só as Armas Calaram o **AD** DRAGÃO

ABC
EDITORA

AF Ablation in Portugal ~25% of all ablations



... AF prevalence in the population with >40 years-old is 2,5%.

Catheter ablation for paroxysmal and persistent atrial fibrillation

Chen HS, et al. Cochrane Database Syst Rev 2012

- **Primary objective:**

to assess the beneficial and harmful effects of catheter ablation in comparison with medical treatment in pts with paroxysmal and persistent AF.

- **Secondary objective:**

to determine the best regimen of ablation.

32 RCT; 3560 patients

There is limited evidence to suggest that catheter ablation may be a better treatment option compared to medical therapies in the management of persistent AF.

This review was also unable to recommend the best ablation method.

O TRATAMENTO ABLATIVO DA FA PERSISTENTE DE LONGA-DURAÇÃO CONSTITUI UM IMPORTANTE DESAFIO.

A EFICÁCIA DESTA ABLAÇÃO DEPENDERÁ DA IDENTIFICAÇÃO/LOCALIZAÇÃO DOS MECANISMOS COMPLEXOS QUE REPRESENTAM O SUBSTRATO ARRÍTMICO CAPAZ DE MANTER A ARRITMIA E SUA ELIMINAÇÃO/MODIFICAÇÃO COM SEGURANÇA.

Mapeamento Electrocardiográfico Não Invasivo




ECVUE
noninvasive dynamic mapping in a beat

cardioInsight
noninvasive dynamic mapping in a beat



*FA persistente »»»»
(rotor porção inferior
parede posterior AE)*



“Both Prof. Adragao and Prof. Oliveira are noted as National Coordinators for Atrial Fibrillation Ablation LongTerm Registry for Portugal.”

EURObservational Research Programme
European Society of Cardiology

eorp@escardio.org